Simple benchmark for complex dose finding studies

Biometrics

Volumn 70, Issue 2, 2014, Pages 389-397

  Cheung, Ying Kuen ^a  

^a Columbia University ^*  (United States)

Author keywords

Combination therapy; Efficacy toxicity tradeoff; Multiple toxicities; Phase I trials; Phase I II trials; Utility scores

Indexed keywords

COMBINATION THERAPY; DOSE FINDING; EFFICACY-TOXICITY TRADEOFF; MULTIPLE TOXICITY; PHASE I; PHASE I TRIAL; PHASE I/II TRIAL; SIMPLE++; UTILITY SCORE;

TOXICITY;

ACCURACY ASSESSMENT; ALGORITHM; BENCHMARKING; BIOMETRY; DISEASE TREATMENT; DOSE-RESPONSE RELATIONSHIP;

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; FIBRINOLYTIC AGENT; PYRAZINE DERIVATIVE;

ALGORITHM; BAYES THEOREM; BIOMETRY; COMPUTER SIMULATION; DOSE RESPONSE; HUMAN; LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES; QUALITY CONTROL; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; STROKE; URINARY BLADDER NEOPLASMS;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BAYES THEOREM; BENCHMARKING; BIOMETRY; BORONIC ACIDS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HUMANS; LYMPHOMA; MODELS, STATISTICAL; PYRAZINES; STROKE; URINARY BLADDER NEOPLASMS;

EID: 84902319177     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/biom.12158     Document Type: Article

References (22)

1. Bekele, B. N. and Thall, P. F. (2004). Dose finding based on multiple toxicities in a soft tissue sarcoma trial. Journal of the American Statistical Association 99, 26-35.
2. Braun, T. (2002). The bivariate continual reassessment method: Extending the CRM to phase I trials of two competing outcomes. Controlled Clinical Trials 23, 240-256.
3. Cheung, Y. K. (2005). Coherence principles in dose finding studies. Biometrika 92, 863-873.
4. Cheung, Y. K. (2007). Sequential implementation of stepwise procedures identifying the maximum tolerated dose. Journal of the American Statistical Association 102, 1448-1461.
5. Cheung, Y. K. (2010). Stochastic approximation and modern model-based designs for dose finding clinical trials. Statistical Science 25, 191-201.
6. Cheung, Y. K. (2013). Sample size formulae for the Bayesian continual reassessment method. Clinical Trials 10, 852-861.
7. Dragalin, V. and Fedorov, V. V. (2006). Adaptive designs for dose-finding based on efficacy-toxicity response. Journal of Statistical Planning and Inference 136, 1800-1823.
8. Durham, S. D., Flournoy, N., and Rosenberger, W. F. (1997). A random walk rule for phase I clinical trials. Biometrics 53, 745-760.
9. Fleiss, J., Levin, B., and Paik, M. C. (2003). Statistical Methods for Rates and Proportions. New York: Wiley-Interscience.
10. Houede, J., Thall, P. F., Nguyen, H., Paoletti, X., and Kramar, A. (2010). Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials. Biometrics 66, 532-540.
11. Lee, S. M., Cheng, B., and Cheung, Y. K. (2011). Continual reassessment method with multiple toxicity constraints. Biostatistics 12, 386-398.
12. Lee, S. M., Horseman D. L., Martin, P., Leonard, J. P., and Cheung, Y. K. (2012). Toxicity burden score: A novel approach to summarize multiple toxic effects. Annals of Oncology 23, 537-541.
13. Lin, Y. and Shih, W. J. (2001). Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics 2, 203-215.
14. Liu, G., Rosenberger, W. F., and Haines, L. M. (2006). Sequential designs for logistic phase I clinical trials. Journal of Biopharmaceutical Statistics 16, 605-621.
15. O'Quigley, J., Pepe, M., and Fisher, L. (1990). Continual reassessment method: A practical design for phase I clinical studies in cancer. Biometrics 46, 33-48.
16. O'Quigley, J., Hughes, M. D., and Fenton, T. (2001). Dose-finding designs for HIV studies. Biometrics 57, 1018-1029.
17. O'Quigley, J., Paoletti, X., and Maccario, J. (2002). Non-parametric optimal design in dose finding studies. Biostatistics 3, 51-56.
18. Paul, R. K., Rosenberger, W. F., and Flournoy, N. (2004). Quantile estimation following non-parametric phase I clinical trials with ordinal response. Statistics in Medicine 23, 2483-2495.
19. Thall, P. F. and Cook, J. D. (2004). Dose finding based on efficacy-toxicity trade-offs. Biometrics 60, 684-693.
20. Thall, P. F. and Russell, K. T. (1998). A strategy for dose finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 54, 251-264.
21. Yin, G., Li, Y., and Ji, Y. (2006). Bayesian dose finding in phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics 62, 777-784.
22. Yuan, Z., Chappell, R., and Bailey, H. (2007). The continual reassessment method for multiple toxicity grades: A Bayesian quasi-likelihood approach. Biometrics 63, 173-179.